Evolocumab vs Laroprovstat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Evolocumab · Repatha
Marketed by Amgen
NCT01516879 · Phase 3 · completed
The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
Reported efficacy
Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) (met)
Result source: NCT02392559
Laroprovstat
Developed by AstraZeneca
NCT06173570 · Phase 2 · completed
The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).
Next expected readout: January 2027 · NCT07000136 (registry estimate)
Reported efficacy
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)
Result source: NCT06173570
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Evolocumab | Laroprovstat |
|---|---|---|
| LDL-C, % change | -50.1% vs 6.8%−57 vs placeboNCT0151687957 other results
| -46.6% vs 4.1%−50.7 vs placeboNCT061735707 other results
|
| Non-HDL-C, % change | -41.8% vs 8.4%−50.3 vs placeboNCT0151687950 other results
| -41.6% vs 3.5%−45.2 vs placeboNCT061735707 other results
|
| ApoB, % change | -41.3% vs 2.9%−44.2 vs placeboNCT0151687953 other results
| -37.0% vs 2.9%−39.9 vs placeboNCT061735707 other results
|
| Lp(a), % change | -27.7% vs -5.4%−22.3 vs placeboNCT0151687952 other results
| -19.4% vs 0%−19.4 vs placeboNCT061735703 other results
|
| 3-point MACE (% with event) | 7.9% vs 9.9%−2 vs placeboNCT017646335 other results
| —Trial running · NCT06834932 |
LDL-C, % change
- Evolocumab
- -50.1% vs 6.8%−57 vs placeboNCT01516879
57 other results
- -44.5% vs -6.2% NCT02392559
- -61.6% vs 8.1% NCT01763866
- -58.2% vs 8.1% NCT01763866
- -61.8% vs 8.1% NCT01763866
- -58.7% vs 8.1% NCT01763866
- -60.1% vs 8.1% NCT01763866
- -59.4% vs 8.1% NCT01763866
- -58.9% vs 8.1% NCT01763866
- -52.4% vs 8.1% NCT01763866
- -65.9% vs 8.1% NCT01763866
- -57.0% vs 8.1% NCT01763866
- -57.0% vs -1.3% NCT01763827
- -56.1% vs -1.3% NCT01763827
- -64.7% vs 7.1% NCT02662569
- -62.3% vs 7.1% NCT02662569
- -54.3% vs -1.1% NCT02739984
- -69.0% vs 4.9% NCT02662569
- -61.3% vs 5.5% NCT01763918
- -55.7% vs 5.5% NCT01763918
- -55.2% vs 1.7% NCT02833844
- -73.6% vs 1.4% NCT01953328
- -64.6% vs 1.4% NCT01953328
- -74.5% vs 1.4% NCT01953328
- -70.4% vs 1.4% NCT01953328
- -73.7% vs -0.4% NCT01953328
- -70.0% vs -0.4% NCT01953328
- -74.8% vs -0.4% NCT01953328
- -76.9% vs -0.4% NCT01953328
- -61.4% vs 7.5% NCT01763866
- -62.5% vs 7.5% NCT01763866
- -61.8% vs 7.5% NCT01763866
- -65.0% vs 7.5% NCT01763866
- -59.3% vs 7.5% NCT01763866
- -63.8% vs 7.5% NCT01763866
- -59.1% vs 7.5% NCT01763866
- -62.9% vs 7.5% NCT01763866
- -66.2% vs 7.5% NCT01763866
- -62.5% vs 7.5% NCT01763866
- -56.9% vs -1.4% NCT01763827
- -58.8% vs -1.4% NCT01763827
- -61.2% vs 2.3% NCT01763918
- -63.3% vs 2.3% NCT01763918
- -65.3% vs 4.9% NCT02662569
- -65.0% vs -0.8% NCT02739984
- -23.1% vs 7.9% NCT01588496
- -56.1% vs -18.1% NCT01763905
- -52.6% vs -18.1% NCT01763905
- -52.8% vs -16.7% NCT01984424
- -54.5% vs -16.7% NCT01984424
- -56.1% vs -19.2% NCT01763905
- -55.3% vs -19.2% NCT01763905
- -54.4% vs 3.2% NCT01516879
- -59.0% vs 1.6% NCT02729025
- -48.0% vs -5.9% NCT02392559
- -57.8% vs -0.7% NCT02189837
- -83.2% vs -0.7% NCT02189837
- -25.6% vs 4.2% NCT01588496
- Laroprovstat
- -46.6% vs 4.1%−50.7 vs placeboNCT06173570
7 other results
- -41.1% vs 4.1% NCT06173570
- -33.8% vs 4.1% NCT06173570
- -31.2% vs 4.1% NCT06173570
- -46.4% vs 3.4% NCT06173570
- -40.5% vs 3.4% NCT06173570
- -33.4% vs 3.4% NCT06173570
- -30.5% vs 3.4% NCT06173570
Non-HDL-C, % change
- Evolocumab
- -41.8% vs 8.4%−50.3 vs placeboNCT01516879
50 other results
- -41.2% vs -6.1% NCT02392559
- -53.4% vs 7.9% NCT01763866
- -52.2% vs 7.9% NCT01763866
- -54.8% vs 7.9% NCT01763866
- -50.0% vs 7.9% NCT01763866
- -52.0% vs 7.9% NCT01763866
- -51.6% vs 7.9% NCT01763866
- -51.0% vs 7.9% NCT01763866
- -46.4% vs 7.9% NCT01763866
- -59.0% vs 7.9% NCT01763866
- -51.0% vs 7.9% NCT01763866
- -50.1% vs 1.5% NCT01763827
- -49.7% vs 1.5% NCT01763827
- -52.9% vs 5.9% NCT02662569
- -56.2% vs 5.3% NCT01763918
- -49.7% vs 5.3% NCT01763918
- -55.8% vs 5.9% NCT02662569
- -46.9% vs -0.6% NCT02739984
- -48.1% vs 2.9% NCT02833844
- -67.8% vs -0.1% NCT01953328
- -58.0% vs -0.1% NCT01953328
- -68.9% vs -0.1% NCT01953328
- -63.3% vs -0.1% NCT01953328
- -68.5% vs -1.6% NCT01953328
- -61.7% vs -1.6% NCT01953328
- -69.7% vs -1.6% NCT01953328
- -69.1% vs -1.6% NCT01953328
- -53.5% vs 7.0% NCT01763866
- -56.1% vs 7.0% NCT01763866
- -54.4% vs 7.0% NCT01763866
- -56.3% vs 7.0% NCT01763866
- -52.6% vs 7.0% NCT01763866
- -55.5% vs 7.0% NCT01763866
- -52.1% vs 7.0% NCT01763866
- -55.7% vs 7.0% NCT01763866
- -59.3% vs 7.0% NCT01763866
- -56.0% vs 7.0% NCT01763866
- -50.2% vs 1.3% NCT01763827
- -52.0% vs 1.3% NCT01763827
- -59.1% vs 4.3% NCT02662569
- -55.8% vs 2.7% NCT01763918
- -57.3% vs 2.7% NCT01763918
- -56.6% vs 4.3% NCT02662569
- -56.6% vs -0.1% NCT02739984
- -48.6% vs -16.5% NCT01763905
- -46.1% vs -16.5% NCT01763905
- -45.7% vs -14.6% NCT01984424
- -47.4% vs -14.4% NCT01984424
- -48.7% vs -17.2% NCT01763905
- -49.1% vs -17.2% NCT01763905
- Laroprovstat
- -41.6% vs 3.5%−45.2 vs placeboNCT06173570
7 other results
- -41.4% vs 2.9% NCT06173570
- -35.1% vs 3.5% NCT06173570
- -34.8% vs 2.9% NCT06173570
- -29.9% vs 3.5% NCT06173570
- -29.4% vs 2.9% NCT06173570
- -26.9% vs 3.5% NCT06173570
- -26.1% vs 2.9% NCT06173570
ApoB, % change
- Evolocumab
- -41.3% vs 2.9%−44.2 vs placeboNCT01516879
53 other results
- -34.9% vs -2.4% NCT02392559
- -50.9% vs 6.3% NCT01763866
- -47.1% vs 6.3% NCT01763866
- -49.8% vs 6.3% NCT01763866
- -46.5% vs 6.3% NCT01763866
- -50.1% vs 6.3% NCT01763866
- -48.6% vs 6.3% NCT01763866
- -45.6% vs 6.3% NCT01763866
- -43.7% vs 6.3% NCT01763866
- -56.0% vs 6.3% NCT01763866
- -49.2% vs 6.3% NCT01763866
- -47.2% vs 1.8% NCT01763827
- -46.6% vs 1.8% NCT01763827
- -49.7% vs 3.2% NCT02662569
- -49.8% vs 4.6% NCT01763918
- -44.8% vs 4.6% NCT01763918
- -53.9% vs 3.2% NCT02662569
- -40.3% vs 1.8% NCT02739984
- -45.1% vs 2.6% NCT02833844
- -55.0% vs 2.0% NCT02662569
- -50.2% vs 2.3% NCT02739984
- -48.3% vs 3.3% NCT02729025
- -64.8% vs -2.5% NCT01953328
- -54.8% vs -2.5% NCT01953328
- -62.8% vs -2.5% NCT01953328
- -58.0% vs -2.5% NCT01953328
- -64.8% vs -4.3% NCT01953328
- -58.5% vs -4.3% NCT01953328
- -64.4% vs -4.3% NCT01953328
- -64.2% vs -4.3% NCT01953328
- -51.0% vs 5.1% NCT01763866
- -51.4% vs 5.1% NCT01763866
- -49.1% vs 5.1% NCT01763866
- -53.3% vs 5.1% NCT01763866
- -49.8% vs 5.1% NCT01763866
- -53.6% vs 5.1% NCT01763866
- -47.1% vs 5.1% NCT01763866
- -53.0% vs 5.1% NCT01763866
- -55.6% vs 5.1% NCT01763866
- -54.4% vs 5.1% NCT01763866
- -47.0% vs 1.5% NCT01763827
- -49.4% vs 1.5% NCT01763827
- -56.4% vs 2.0% NCT02662569
- -49.6% vs 2.2% NCT01763918
- -52.8% vs 2.2% NCT01763918
- -19.2% vs 4.0% NCT01588496
- -20.2% vs 2.6% NCT01588496
- -45.8% vs -12.9% NCT01763905
- -43.1% vs -12.9% NCT01763905
- -43.5% vs -11.7% NCT01984424
- -45.3% vs -11.4% NCT01984424
- -45.9% vs -13.7% NCT01763905
- -46.0% vs -13.7% NCT01763905
- Laroprovstat
- -37.0% vs 2.9%−39.9 vs placeboNCT06173570
7 other results
- -36.9% vs 2.4% NCT06173570
- -34.3% vs 2.9% NCT06173570
- -33.9% vs 2.4% NCT06173570
- -25.4% vs 2.9% NCT06173570
- -24.5% vs 2.4% NCT06173570
- -24.1% vs 2.9% NCT06173570
- -23.4% vs 2.4% NCT06173570
Lp(a), % change
- Evolocumab
- -27.7% vs -5.4%−22.3 vs placeboNCT01516879
52 other results
- -12.8% vs 1.1% NCT02729025
- -25.9% vs 11.4% NCT01763866
- -20.3% vs 11.4% NCT01763866
- -24.6% vs 11.4% NCT01763866
- -24.7% vs 11.4% NCT01763866
- -25.1% vs 11.4% NCT01763866
- -20.9% vs 11.4% NCT01763866
- -26.1% vs 11.4% NCT01763866
- -22.0% vs 11.4% NCT01763866
- -38.1% vs 11.4% NCT01763866
- -29.2% vs 11.4% NCT01763866
- -20.4% vs 0% NCT01763827
- -17.8% vs 0% NCT01763827
- -37.9% vs 26.5% NCT02662569
- -25.2% vs 7.4% NCT02739984
- -42.3% vs 16.9% NCT02662569
- -22.9% vs 6.7% NCT01763918
- -21.6% vs 6.7% NCT01763918
- -35.9% vs 26.5% NCT02662569
- -16.4% vs 10.3% NCT02833844
- -45.7% vs 10.8% NCT01953328
- -41.7% vs 10.8% NCT01953328
- -41.9% vs 10.8% NCT01953328
- -45.7% vs 10.8% NCT01953328
- -45.0% vs 6.5% NCT01953328
- -49.5% vs 6.5% NCT01953328
- -26.0% vs 11.4% NCT01763866
- -22.6% vs 11.4% NCT01763866
- -24.0% vs 11.4% NCT01763866
- -27.5% vs 11.4% NCT01763866
- -24.3% vs 11.4% NCT01763866
- -23.2% vs 11.4% NCT01763866
- -25.0% vs 11.4% NCT01763866
- -25.9% vs 11.4% NCT01763866
- -38.6% vs 11.4% NCT01763866
- -32.2% vs 11.4% NCT01763866
- -18.4% vs 0% NCT01763827
- -19.2% vs 0% NCT01763827
- -24.0% vs 5.3% NCT01763918
- -25.6% vs 5.3% NCT01763918
- -38.6% vs 16.9% NCT02662569
- -30.9% vs 9.6% NCT02739984
- -9.4% vs 2.4% NCT01588496
- -46.0% vs 6.5% NCT01953328
- -43.0% vs 6.5% NCT01953328
- -12.7% vs -1.4% NCT01588496
- -27.0% vs -1.7% NCT01763905
- -22.1% vs -1.7% NCT01763905
- -21.1% vs 0.2% NCT01984424
- -22.7% vs -1.6% NCT01984424
- -26.2% vs -2.3% NCT01763905
- -23.7% vs -2.3% NCT01763905
- Laroprovstat
- -19.4% vs 0%−19.4 vs placeboNCT06173570
3 other results
- -19.6% vs 0% NCT06173570
- -11.2% vs 0% NCT06173570
- -7.5% vs 0% NCT06173570
3-point MACE (% with event)
- Evolocumab
- 7.9% vs 9.9%−2 vs placeboNCT01764633
5 other results
- 6.7% vs 8.3% NCT01764633
- 5.5% vs 6.8% NCT01764633
- 4.3% vs 5.2% NCT01764633
- 3.1% vs 3.7% NCT01764633
- 1.6% vs 1.9% NCT01764633
- Laroprovstat
- —Trial running · NCT06834932
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Evolocumab: 8 of 8 rows · Laroprovstat: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Evolocumab Rows use multiple source trials | Laroprovstat |
|---|---|---|
| HDL-C percent change · % of baseline | 5.54% (n=110) vs -0.99% (n=56) placeboQ2Wa,b,c,d NCT01763866 · Phase 3 show 19 more doses7.04% (n=110) vs 0.22% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 7.66% (n=110) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 7.88% (n=110) vs 0.22% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 8.44% (n=109) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 9.09% (n=109) vs 0.22% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 7.76% (n=110) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 7.36% (n=110) vs 0.22% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 4.86% (n=111) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 4.65% (n=111) vs 0.22% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 6.35% (n=112) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 5.57% (n=112) vs 0.22% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 6.23% (n=113) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 6.07% (n=113) vs 0.22% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 7.72% (n=115) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 7.18% (n=115) vs 0.22% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 10.35% (n=112) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 10.92% (n=112) vs 0.22% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 6.71% (n=115) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 6.41% (n=115) vs 0.22% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 | 4.66% (n=85) vs 3.65% (n=86) placebo @ 12wk30 mga,b,c,d NCT06173570 · Phase 2 show 7 more doses4.65% (n=85) vs 3.11% (n=86) placebo @ 12wk30 mg NCT06173570 · Phase 2 1.97% (n=84) vs 3.65% (n=86) placebo @ 12wk10 mg NCT06173570 · Phase 2 2.17% (n=84) vs 3.11% (n=86) placebo @ 12wk10 mg NCT06173570 · Phase 2 4.03% (n=85) vs 3.65% (n=86) placebo @ 12wk3 mg NCT06173570 · Phase 2 3.66% (n=85) vs 3.11% (n=86) placebo @ 12wk3 mg NCT06173570 · Phase 2 0.12% (n=86) vs 3.65% (n=86) placebo @ 12wk1 mg NCT06173570 · Phase 2 0.8% (n=86) vs 3.11% (n=86) placebo @ 12wk1 mg NCT06173570 · Phase 2 |
| Total Cholesterol percent change · % of baseline | -32.3% (n=599) vs 2.85% (n=302) placebo @ 12wkb,c,d NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 11 other source trials-38.64% (n=325) vs 2.89% (n=164) placeboQ2W NCT02662569 · Phase 3 · registry result, not featured evidence -37.82% (n=325) vs 4.4% (n=164) placebo @ 12wkQ2W NCT02662569 · Phase 3 · registry result, not featured evidence -39.74% (n=332) vs 2.89% (n=164) placeboQM NCT02662569 · Phase 3 · registry result, not featured evidence -35.22% (n=332) vs 4.4% (n=164) placebo @ 12wkQM NCT02662569 · Phase 3 · registry result, not featured evidence -38.04% (n=145) vs -11.43% (n=73) Ezetimibe NCT01984424 · Phase 3 · registry result, not featured evidence -42.19% (n=280) vs -1.13% (n=141) placebo NCT02739984 · Phase 3 · registry result, not featured evidence -34.97% (n=280) vs -1.23% (n=141) placebo @ 12wk NCT02739984 · Phase 3 · registry result, not featured evidence -44.04% (n=51) vs -1.7% (n=49) placebo @ 12wkQ2W NCT01953328 · Phase 3 · registry result, not featured evidence -40.88% (n=51) vs -1.7% (n=49) placebo @ 12wkQM NCT01953328 · Phase 3 · registry result, not featured evidence -47.14% (n=50) vs -1.7% (n=49) placebo @ 12wkQ2W NCT01953328 · Phase 3 · registry result, not featured evidence -39.06% (n=50) vs -1.7% (n=49) placebo @ 12wkQM NCT01953328 · Phase 3 · registry result, not featured evidence | -27.06% (n=85) vs 2.29% (n=86) placebo @ 12wk30 mga,b,c,d NCT06173570 · Phase 2 show 7 more doses-26.9% (n=85) vs 1.73% (n=86) placebo @ 12wk30 mg NCT06173570 · Phase 2 -24.84% (n=84) vs 2.29% (n=86) placebo @ 12wk10 mg NCT06173570 · Phase 2 -24.54% (n=84) vs 1.73% (n=86) placebo @ 12wk10 mg NCT06173570 · Phase 2 -20.09% (n=85) vs 2.29% (n=86) placebo @ 12wk3 mg NCT06173570 · Phase 2 -19.8% (n=85) vs 1.73% (n=86) placebo @ 12wk3 mg NCT06173570 · Phase 2 -18.93% (n=86) vs 2.29% (n=86) placebo @ 12wk1 mg NCT06173570 · Phase 2 -18.23% (n=86) vs 1.73% (n=86) placebo @ 12wk1 mg NCT06173570 · Phase 2 |
| Triglycerides percent change · % of baseline | -5.61% (n=110) vs 6.49% (n=56) placeboQ2Wa,b,c,d NCT01763866 · Phase 3 show 19 more doses-3.79% (n=110) vs 8.27% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -13.38% (n=110) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -13.26% (n=110) vs 8.27% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 -9.27% (n=109) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -10.07% (n=109) vs 8.27% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -6.36% (n=110) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -1.1% (n=110) vs 8.27% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 -9.15% (n=111) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -5.58% (n=111) vs 8.27% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -15.43% (n=112) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -10.51% (n=112) vs 8.27% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 -10.28% (n=113) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -4.46% (n=113) vs 8.27% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -7.26% (n=115) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -6.88% (n=115) vs 8.27% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 -11.67% (n=112) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -13.71% (n=112) vs 8.27% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -15.93% (n=115) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -14.65% (n=115) vs 8.27% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 | -0.44% (n=85) vs 9.56% (n=86) placebo @ 12wk30 mga,b,c,d NCT06173570 · Phase 2 show 7 more doses-0.83% (n=85) vs 9.04% (n=86) placebo @ 12wk30 mg NCT06173570 · Phase 2 1.93% (n=84) vs 9.56% (n=86) placebo @ 12wk10 mg NCT06173570 · Phase 2 1.72% (n=84) vs 9.04% (n=86) placebo @ 12wk10 mg NCT06173570 · Phase 2 2.9% (n=85) vs 9.56% (n=86) placebo @ 12wk3 mg NCT06173570 · Phase 2 2.17% (n=85) vs 9.04% (n=86) placebo @ 12wk3 mg NCT06173570 · Phase 2 3.06% (n=86) vs 9.56% (n=86) placebo @ 12wk1 mg NCT06173570 · Phase 2 2.81% (n=86) vs 9.04% (n=86) placebo @ 12wk1 mg NCT06173570 · Phase 2 |
| VLDL-C percent change · % of baseline | -6.85% (n=110) vs 6.51% (n=56) placeboQ2Wa,b,c,d NCT01763866 · Phase 3 show 19 more doses-6.16% (n=110) vs 8.32% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -11.77% (n=110) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -11.73% (n=110) vs 8.32% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 -8.96% (n=109) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -9.69% (n=109) vs 8.32% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -6.38% (n=110) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -1.06% (n=110) vs 8.32% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 -9.09% (n=111) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -6.1% (n=111) vs 8.32% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -15.05% (n=112) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -9.95% (n=112) vs 8.32% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 -12.22% (n=113) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -8.2% (n=113) vs 8.32% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -7.25% (n=115) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -6.28% (n=115) vs 8.32% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 -14.57% (n=112) vs 6.51% (n=56) placeboQ2W NCT01763866 · Phase 3 -14.83% (n=112) vs 8.32% (n=56) placebo @ 12wkQ2W NCT01763866 · Phase 3 -16.5% (n=115) vs 6.51% (n=56) placeboQM NCT01763866 · Phase 3 -15.86% (n=115) vs 8.32% (n=56) placebo @ 12wkQM NCT01763866 · Phase 3 | 0.46% (n=85) vs 7.19% (n=86) placebo @ 12wk30 mga,b,c,d NCT06173570 · Phase 2 show 7 more doses0.42% (n=85) vs 6.74% (n=86) placebo @ 12wk30 mg NCT06173570 · Phase 2 2.21% (n=84) vs 7.19% (n=86) placebo @ 12wk10 mg NCT06173570 · Phase 2 1.77% (n=84) vs 6.74% (n=86) placebo @ 12wk10 mg NCT06173570 · Phase 2 4.02% (n=85) vs 7.19% (n=86) placebo @ 12wk3 mg NCT06173570 · Phase 2 2.67% (n=85) vs 6.74% (n=86) placebo @ 12wk3 mg NCT06173570 · Phase 2 1.13% (n=86) vs 7.19% (n=86) placebo @ 12wk1 mg NCT06173570 · Phase 2 0.81% (n=86) vs 6.74% (n=86) placebo @ 12wk1 mg NCT06173570 · Phase 2 |
| Dropout rate | 5.6%e NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results0%Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0.7% NCT01764633 · Phase 3 3.2% NCT02207634 · Phase 3 1.8%Q2W NCT01763866 · Phase 3 2.7%QM NCT01763866 · Phase 3 7.3%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 5.4%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 10.5%Q2W NCT01763866 · Phase 3 2.6%QM NCT01763866 · Phase 3 2.7%Q2W NCT01763866 · Phase 3 1.7%QM NCT01763866 · Phase 3 3.9%Q2W NCT01763827 · Phase 3 1.3%QM NCT01763827 · Phase 3 9%Q2W NCT01763918 · Phase 3 1.8%QM NCT01763918 · Phase 3 1%420 mg QM NCT02392559 · Phase 3 —420 mg QM NCT02392559 · Phase 3 30.2% NCT01624142 · Phase 2/3 3%420 mg QM NCT02624869 · Phase 3 2%420 mg QM NCT02624869 · Phase 3 15.4%420 mg QM NCT02624869 · Phase 3 38.3% NCT04608474 · Phase 4 · registry result, not featured evidence 0%HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 0%NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence 14.5% NCT03689946 · Phase 3 · registry result, not featured evidence 16.4%Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence —Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence 3.7% NCT03570697 · Phase 3 · registry result, not featured evidence — NCT02833844 · Phase 3 · registry result, not featured evidence 2.6%Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT02634580 · Phase 3 · registry result, not featured evidence —QM NCT02634580 · Phase 3 · registry result, not featured evidence 1.5%420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence 3.2% NCT02304484 · Phase 3 · registry result, not featured evidence 1.8%Q2W NCT02662569 · Phase 3 · registry result, not featured evidence 1.2%QM NCT02662569 · Phase 3 · registry result, not featured evidence 4.8% NCT01984424 · Phase 3 · registry result, not featured evidence 0.7% NCT02739984 · Phase 3 · registry result, not featured evidence 3.3% NCT01813422 · Phase 3 · registry result, not featured evidence 13%Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence 9.5%Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 8.7%Q2W NCT01763905 · Phase 3 · registry result, not featured evidence 1%QM NCT01763905 · Phase 3 · registry result, not featured evidence 6.1%Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence 2.4%Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence 5.4%Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence 1.3%Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence —All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence —All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence 6.8%Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination —SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination | 5.9%30 mgf NCT06173570 · Phase 2 show 3 more results1.2%10 mg NCT06173570 · Phase 2 4.7%3 mg NCT06173570 · Phase 2 5.8%1 mg NCT06173570 · Phase 2 |
| Discontinued due to AEs | —e NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results—Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 — NCT01764633 · Phase 3 — NCT02207634 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763827 · Phase 3 —QM NCT01763827 · Phase 3 —Q2W NCT01763918 · Phase 3 —QM NCT01763918 · Phase 3 —420 mg QM NCT02392559 · Phase 3 —420 mg QM NCT02392559 · Phase 3 — NCT01624142 · Phase 2/3 —420 mg QM NCT02624869 · Phase 3 —420 mg QM NCT02624869 · Phase 3 —420 mg QM NCT02624869 · Phase 3 6.2% NCT04608474 · Phase 4 · registry result, not featured evidence —HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence —NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence — NCT03403374 · Phase 4 · registry result, not featured evidence — NCT03689946 · Phase 3 · registry result, not featured evidence —Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence —Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence — NCT03570697 · Phase 3 · registry result, not featured evidence — NCT02833844 · Phase 3 · registry result, not featured evidence —Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT02634580 · Phase 3 · registry result, not featured evidence —QM NCT02634580 · Phase 3 · registry result, not featured evidence —420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence — NCT02304484 · Phase 3 · registry result, not featured evidence —Q2W NCT02662569 · Phase 3 · registry result, not featured evidence —QM NCT02662569 · Phase 3 · registry result, not featured evidence — NCT01984424 · Phase 3 · registry result, not featured evidence — NCT02739984 · Phase 3 · registry result, not featured evidence — NCT01813422 · Phase 3 · registry result, not featured evidence —Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence —Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT01953328 · Phase 3 · registry result, not featured evidence —QM NCT01953328 · Phase 3 · registry result, not featured evidence —Q2W NCT01953328 · Phase 3 · registry result, not featured evidence —QM NCT01953328 · Phase 3 · registry result, not featured evidence —Q2W NCT01763905 · Phase 3 · registry result, not featured evidence —QM NCT01763905 · Phase 3 · registry result, not featured evidence —Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence —Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence —Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence —Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence —All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence —All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence —Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination —SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination | 2.4%30 mgf NCT06173570 · Phase 2 show 3 more results0%10 mg NCT06173570 · Phase 2 0%3 mg NCT06173570 · Phase 2 1.2%1 mg NCT06173570 · Phase 2 |
| Serious AEs | 5.5%e NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results—Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 24.8% NCT01764633 · Phase 3 21.6% NCT02207634 · Phase 3 3.6%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 2.8%Q2W NCT01763866 · Phase 3 0.9%QM NCT01763866 · Phase 3 0.9%Q2W NCT01763866 · Phase 3 2.7%QM NCT01763866 · Phase 3 2.7%Q2W NCT01763866 · Phase 3 2.6%QM NCT01763866 · Phase 3 1.8%Q2W NCT01763866 · Phase 3 0.9%QM NCT01763866 · Phase 3 2%Q2W NCT01763827 · Phase 3 0.7%QM NCT01763827 · Phase 3 2.7%Q2W NCT01763918 · Phase 3 3.6%QM NCT01763918 · Phase 3 —420 mg QM NCT02392559 · Phase 3 1%420 mg QM NCT02392559 · Phase 3 27.4% NCT01624142 · Phase 2/3 2%420 mg QM NCT02624869 · Phase 3 4.1%420 mg QM NCT02624869 · Phase 3 16.7%420 mg QM NCT02624869 · Phase 3 0% NCT04608474 · Phase 4 · registry result, not featured evidence 5.3%HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 4.5%NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 6.7% NCT03403374 · Phase 4 · registry result, not featured evidence 0% NCT03689946 · Phase 3 · registry result, not featured evidence —Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence 41.8%Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence 16.3% NCT03570697 · Phase 3 · registry result, not featured evidence 3.3% NCT02833844 · Phase 3 · registry result, not featured evidence —Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination 7.9%Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination 14.4%Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination 15.1%Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT02634580 · Phase 3 · registry result, not featured evidence 0%QM NCT02634580 · Phase 3 · registry result, not featured evidence 3.1%420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence 19.9% NCT02304484 · Phase 3 · registry result, not featured evidence 3.1%Q2W NCT02662569 · Phase 3 · registry result, not featured evidence 6.6%QM NCT02662569 · Phase 3 · registry result, not featured evidence 6.2% NCT01984424 · Phase 3 · registry result, not featured evidence 5% NCT02739984 · Phase 3 · registry result, not featured evidence 27.9% NCT01813422 · Phase 3 · registry result, not featured evidence 0%Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence 5%Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 2%QM NCT01953328 · Phase 3 · registry result, not featured evidence 4.9%Q2W NCT01763905 · Phase 3 · registry result, not featured evidence 1%QM NCT01763905 · Phase 3 · registry result, not featured evidence 1.2%Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence 0%Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence 2.7%Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence 4%Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence 22%All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence 19.6%All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence —Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination 8.2%SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination | 1.2%30 mgf NCT06173570 · Phase 2 show 3 more results2.4%10 mg NCT06173570 · Phase 2 2.4%3 mg NCT06173570 · Phase 2 2.3%1 mg NCT06173570 · Phase 2 |
| Most frequent reported AEs | e nasopharyngitis 10.5% (placebo 9.6%) upper respiratory tract infection 9.3% (placebo 6.3%) influenza 7.5% (placebo 6.3%) NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 54 more resultsbronchitis 12.5% (placebo 0%) dyspepsia 12.5% (placebo 0%) pain 12.5% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 influenza 9.1% (placebo 0%) upper respiratory tract infection 9.1% (placebo 6.3%) gastroenteritis 6.1% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 diabetes mellitus 8.4% (placebo 8%) hypertension 7.8% (placebo 8.4%) nasopharyngitis 7.7% (placebo 7.4%) NCT01764633 · Phase 3 nasopharyngitis 10.3% (placebo 7.5%) hypertension 6.2% (placebo 6.7%) back pain 5.9% (placebo 3.6%) NCT02207634 · Phase 3 Q2W muscle spasms 2.7% (placebo 0%) back pain 1.8% (placebo 0%) diarrhoea 1.8% (placebo 0%) NCT01763866 · Phase 3 QM muscle spasms 3.6% (placebo 0%) back pain 0.9% (placebo 0%) dizziness 0.9% (placebo 0%) NCT01763866 · Phase 3 Q2W diarrhoea 3.7% (placebo 0%) back pain 2.8% (placebo 0%) muscle spasms 1.8% (placebo 0%) NCT01763866 · Phase 3 QM headache 2.7% (placebo 1.8%) diarrhoea 1.8% (placebo 0%) myalgia 1.8% (placebo 3.6%) NCT01763866 · Phase 3 Q2W back pain 1.8% (placebo 0%) headache 1.8% (placebo 1.8%) myalgia 0.9% (placebo 3.6%) NCT01763866 · Phase 3 QM headache 2.7% (placebo 1.8%) back pain 0.9% (placebo 0%) diarrhoea 0.9% (placebo 0%) NCT01763866 · Phase 3 Q2W muscle spasms 1.8% (placebo 0%) back pain 0.9% (placebo 0%) constipation 0.9% (placebo 5.4%) NCT01763866 · Phase 3 QM back pain 1.7% (placebo 0%) diarrhoea 1.7% (placebo 0%) dizziness 1.7% (placebo 0%) NCT01763866 · Phase 3 Q2W back pain 5.4% (placebo 0%) dizziness 2.7% (placebo 0%) muscle spasms 2.7% (placebo 0%) NCT01763866 · Phase 3 QM headache 4.3% (placebo 1.8%) myalgia 2.6% (placebo 3.6%) back pain 1.7% (placebo 0%) NCT01763866 · Phase 3 Q2W headache 3.3% (placebo 3.9%) diarrhoea 2.6% (placebo 6.6%) nasopharyngitis 2% (placebo 1.3%) NCT01763827 · Phase 3 QM diarrhoea 3.3% (placebo 6.6%) headache 3.3% (placebo 3.9%) nasopharyngitis 2% (placebo 1.3%) NCT01763827 · Phase 3 Q2W nasopharyngitis 7.3% (placebo 3.7%) arthralgia 6.4% (placebo 1.9%) headache 3.6% (placebo 1.9%) NCT01763918 · Phase 3 QM nasopharyngitis 10% (placebo 3.7%) back pain 5.5% (placebo 0%) headache 4.5% (placebo 1.9%) NCT01763918 · Phase 3 420 mg QM nasopharyngitis 11.5% (placebo 11.3%) headache 10.6% (placebo 1.9%) oropharyngeal pain 6.7% (placebo 0%) NCT02392559 · Phase 3 allergic skin reaction 4.5% elevated creatine kinase 1.5% NCT04608474 · Phase 4 · registry result, not featured evidence angina pectoris 3.3% arthralgia 3.3% arthritis 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence runny nose 5.5% NCT03689946 · Phase 3 · registry result, not featured evidence hypertension 14.2% (placebo 12.9%) bronchitis 6.9% (placebo 6.4%) upper respiratory tract infection 6.5% (placebo 8.2%) NCT02867813 · Phase 3 · registry result, not featured evidence hypertension 7.5% (placebo 6.2%) myalgia 6.3% (placebo 7.4%) angina pectoris 5% (placebo 8.6%) NCT03570697 · Phase 3 · registry result, not featured evidence back pain 3.9% (placebo 2.5%) influenza like illness 3.9% (placebo 2.5%) diarrhoea 3.6% (placebo 4.5%) NCT02833844 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.2% arthralgia 4.3% upper respiratory tract infection 4.2% NCT01854918 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.6% hypertension 7.5% upper respiratory tract infection 7.4% NCT01854918 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 12.6% upper respiratory tract infection 8.3% arthralgia 6.7% NCT01854918 · Phase 3 · registry result, not featured evidence · combination Q2W pharyngitis 15.8% abdominal distension 10.5% abdominal pain 5.3% NCT02634580 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 23.8% hypertension 9.5% injection site pain 9.5% NCT02634580 · Phase 3 · registry result, not featured evidence 420 mg QM influenza 10.8% (placebo 4.7%) nasopharyngitis 9.2% (placebo 20.3%) myalgia 7.7% (placebo 1.6%) NCT02729025 · Phase 3 · registry result, not featured evidence hypertension 6.4% NCT02304484 · Phase 3 · registry result, not featured evidence Q2W diabetes mellitus 4.6% (placebo 1.2%) nasopharyngitis 2.8% (placebo 3.7%) upper respiratory tract infection 2.8% (placebo 3.7%) NCT02662569 · Phase 3 · registry result, not featured evidence QM diabetes mellitus 4.5% (placebo 1.2%) upper respiratory tract infection 3.9% (placebo 3.7%) nasopharyngitis 3.3% (placebo 3.7%) NCT02662569 · Phase 3 · registry result, not featured evidence myalgia 13.8% nasopharyngitis 9.7% arthralgia 9% NCT01984424 · Phase 3 · registry result, not featured evidence hypertension 3.9% (placebo 0%) diabetes mellitus 2.9% (placebo 3.5%) diarrhoea 2.1% (placebo 2.8%) NCT02739984 · Phase 3 · registry result, not featured evidence myalgia 7% (placebo 5.6%) chest pain 6.8% (placebo 5.4%) hypertension 6% (placebo 7%) NCT01813422 · Phase 3 · registry result, not featured evidence headache 36.4% (placebo 9.5%) influenza like illness 9.1% (placebo 0%) nasopharyngitis 9.1% (placebo 4.8%) NCT02189837 · Phase 3 · registry result, not featured evidence headache 35% (placebo 9.5%) myalgia 10% (placebo 4.8%) nausea 10% (placebo 4.8%) NCT02189837 · Phase 3 · registry result, not featured evidence · combination Q2W nasopharyngitis 13.7% (placebo 9.6%) diabetes mellitus 2% (placebo 0%) gastroenteritis 0% (placebo 1.9%) NCT01953328 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 15.7% (placebo 9.6%) gastroenteritis 5.9% (placebo 1.9%) diabetes mellitus 3.9% (placebo 0%) NCT01953328 · Phase 3 · registry result, not featured evidence Q2W nasopharyngitis 24% (placebo 9.6%) diabetes mellitus 2% (placebo 0%) gastroenteritis 2% (placebo 1.9%) NCT01953328 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 14% (placebo 9.6%) gastroenteritis 4% (placebo 1.9%) diabetes mellitus 0% (placebo 0%) NCT01953328 · Phase 3 · registry result, not featured evidence Q2W myalgia 6.8% muscle spasms 4.9% nasopharyngitis 4.9% NCT01763905 · Phase 3 · registry result, not featured evidence QM headache 11.8% pain in extremity 11.8% myalgia 8.8% NCT01763905 · Phase 3 · registry result, not featured evidence headache 2.7% NCT01849497 · Phase 3 · registry result, not featured evidence headache 5.3% NCT01849497 · Phase 3 · registry result, not featured evidence nasopharyngitis 28.7% upper respiratory tract infection 14.4% back pain 14.2% NCT01439880 · Phase 2 · registry result, not featured evidence nasopharyngitis 30.7% arthralgia 15.8% upper respiratory tract infection 14.3% NCT01439880 · Phase 2 · registry result, not featured evidence nasopharyngitis 16.8% upper respiratory tract infection 8.2% back pain 7% NCT01439880 · Phase 2 · registry result, not featured evidence · combination | show 3 more results |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for 60 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Evolocumab
show 50 more results
show 32 more results
show 26 more results
show 27 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 11 more results
show 5 more results
+ 29 further endpoints in the CSV export.
Laroprovstat
show 7 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evolocumab's landscape · Laroprovstat's landscape